Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253881 | 0.86 | KDM4E (0.38) | PADI4 | |
| SCHEMBL1253880 | 0.86 | KDM4E (0.38) | PADI4 | |
| SCHEMBL726426 | 0.86 | MAPT (0.47) | — | |
| SCHEMBL726425 | 0.86 | MAPT (0.47) | — | |
| SCHEMBL726963 | 0.80 | KDM4E (0.45) | — | |
| SCHEMBL726964 | 0.80 | KDM4E (0.45) | — | |
| SCHEMBL725685 | 0.80 | PADI4 (0.39) | PADI4 | |
| SCHEMBL725684 | 0.80 | PADI4 (0.39) | PADI4 | |
| SCHEMBL726611 | 0.80 | — | — | |
| SCHEMBL726610 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848614-A2 | Acrylamide derivatives as antibiotic agents | Debiopharm International SA (CH) | 2015-03-18 | — | — | EP | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | PADI4 1150/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | PADI4 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.